Company news
Plus Therapeutics, Inc. (NASDAQ:PSTV) news
Plus Therapeutics, Inc. news releases on 6ix. Latest, Jul 31, 2026: Cerenome Launches as an Integrated CNS Oncology Company
Press releases & updates
Cerenome Launches as an Integrated CNS Oncology Company
July 31, 2026
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
July 28, 2026
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
July 21, 2026
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
July 16, 2026
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
July 14, 2026
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
June 30, 2026
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
June 25, 2026
Plus Therapeutics to Provide Business Update Call on June 30, 2026
June 23, 2026
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
June 3, 2026
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
May 26, 2026
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
May 15, 2026
Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases
May 8, 2026
Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
May 7, 2026
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
April 27, 2026
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™
April 23, 2026
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 21, 2026
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
April 14, 2026
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
April 8, 2026
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
April 7, 2026
Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption
April 6, 2026
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives
April 1, 2026
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
March 30, 2026
Plus Therapeutics Announces Reverse Stock Split
March 30, 2026
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors
March 25, 2026
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
March 18, 2026
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
March 11, 2026
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
February 25, 2026
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
January 22, 2026
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
January 21, 2026
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
January 14, 2026
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases
January 8, 2026
Plus Therapeutics Expands CNSide Assay Platform to State of California
December 11, 2025
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
December 9, 2025
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
December 4, 2025
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
December 1, 2025
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
November 24, 2025
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
November 20, 2025
Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
November 17, 2025
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0
November 6, 2025
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights
October 30, 2025
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
October 21, 2025
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
September 25, 2025
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT
September 22, 2025
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT
September 21, 2025
Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory
September 18, 2025
Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria
August 26, 2025
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
August 18, 2025
Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
August 15, 2025
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights
August 14, 2025